Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-24
2007-04-24
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S194000
Reexamination Certificate
active
10387703
ABSTRACT:
This invention concerns compounds of formulathe N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is CH or N; R1is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, mono- or di(C1-6alkyl)amino, Ar1, Ar1NH—, C3-6cycloalkyl, hydroxymethyl or benzoyloxymethyl; R2is hydrogen, C1-6alkyl, amino, aminocarbonyl, mono- or di(C1-6alkyl)amino, C1-6alkyloxycarbonyl, C1-6alkylcarbonylamino, hydroxy or C1-6alkyloxy; R3, R4and R5are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, nitro, amino, cyano, azido, C1-6alkyloxyC1-6alkyl, C1-6alkylthio, C1-6alkyloxycarbonyl or Het1;is Ar2, Ar2CH2— or Het2; Ar1and Ar2optionally substituted phenyl; Het1and Het2are optionally substituted monocyclic heterocycles; having angiogenesis inhibiting activity; their preparation, compositions containing them and their use as a medicine.
REFERENCES:
patent: 5104889 (1992-04-01), Kanai et al.
patent: 6232290 (2001-05-01), Ohki et al.
patent: WO 97/26258 (1997-07-01), None
patent: 99-40108 (1999-08-01), None
Higgins, R.D. et. al., “Squalamine Improves Retinal Neovascularization.” Invest. Oph. & Vis. Sci., May 2000, vol. 41, No. 6, pp. 1507-1512.
PCT International Search Report dated Oct. 2, 1998 for PCT Appln. No. PCT/EP 98/04022 which relates to U.S. Appl. No. 10/387,703.
Auerbach, R. et al. Assays for Angiogeneis: A Review.Pharmac. Ther. 1991 51:1-11.
Blackwell K. et al. Tamoxifen Inhibits Angiogenesis in Estrogen Receptor-Negative Animal Models.Clin. Cancer Res. 2000 6(11):4359-4364 at 4359.
Brem S. Angiogenesis and Cancer Control: From Concept to Therapeutic Trial.Cancer Control, Journal of the Moffitt Cancer Center1999, vol. 6, No. 5, 1-32.
Fidler I et al. The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis.Cell1994 79: 185-188.
Folkman J et al. Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone.Science1983 221: 719-725.
Folkman J et al. Clinical Applications of Research on Angiogenesis.New Eng. J. Med. 1995 333: 1757-1763.
Folkman J. Klagsbrun M. Angiogenic Factors.Science. 1987 235:442-447.
Folkman J. Tumor Angiogenesis: Therapeutic Implications.N Engl J Med. 1971 285:1182-1186.
Folkman J. What is the Evidence that Tumors are Angiogenesis Dependent?J Natl Cancer Inst. 1990; 82:4-6.
Kim K. et al. Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth In Vivo.Nature1993 362:841-844.
Kruger E. A. et al. Endostatin Inhibits Microvessel Formation in the Ex Vivo Rato Aortic Ring Angiogenesis Assay.BBRC2000 268: 183-191.
Kudelka A. et al. Complete Remission of Metastatic Cervical cancer with the Angiogenesis Inhibitor TNP-470New Eng. J. Med. 1998 338:991-992.
Kumar S et al. Psoriasis, Angiogenesis and Hyaluronic Acid.Laboratory Investigation1990 62: 664-665.
Li V. W. et al. Cyclosporine and Angiogenesis in Psoriasis.J. Am. Acad. Derm. 1996 35(6):1019-1020.
Liotta L. et al. Cancer Metastasis and Angiogenesis: An Imbalance of Positive and Negative Regulation.Cell1991 64: 327-336.
Lissbrant I et al. Vascular Density Is a Predictor of Cancer-Specific survival in Prostatic Carcinoma.The Prostate1997 33: 38-45.
Lloyd P et al. Vascular Endothelial Growth Factor in Ocular Fluid of Patients With Diabetic Retinopathy and Other Retinal Disorders.New. Eng. J. Med. 1994 331: 1480-1487.
Los M et al. The Potential Role of Antivascular Therapy in the Adjuvant and Neoadjuvant Treatment of Cancer.Semin Oncol2001 28:93-105.
Millauer B. et al. Glioblastoma Growth Inhibited In Vivo by a Dominant-Negative Flk-1 Mutant.Nature1994 367: 576-579.
Moses M et al. Inhibitors of Angiogenesis.Bio/technology1991 9: 630-634.
Murray, Clifford J., Editor,Angiogenesis Protocols, Human Press, Totowa, NJ 2001 Ch. 13, pp. 185-204.
Nicossia R. F. et al. Endogeneous Regulation of Angiogenesis in the Rat Aorta Model.Am. J. Pathology1997 151(5):1379-1386.
Nissanov, J et al. Methods in Laboratory Investigation: Automatic Vessel Segmentation and Quantification of the Rat Aortic Ring Assay of Angiogenesis.Lab. Investig. 1995 73: 734-739.
O'Reilly M et al. Angiostatin: A Novel Angiogenesis Inhibitor That Mediate the Suppression of Metastases by a Lewis Lung Carcinoma.Cell1994 79: 315-328.
O'Reilly M et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth.Cell1997 88: 277-285.
Perez-Atayde A. et al. Spectrum of Tumor Angiogenesis in the Bone Marrow of Children with Acute-Lymphoblastic Leukemia.Am. J. Pathology1997 150-815-820.
Plate K. et al. Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas In vivo.Nature1992 359:845-848.
Shweiki D et al. Vascular Endothelial Growth Factor Induced by Hypoxia May Mediate Hypoxia-Initiated Angiogenesis.Nature1992 359: 843-845.
Singh R. et al. Interferons α and β Down-Regulate the Expression of Basic Fibroblast Growth Factor in Human Carcinomas.Proc.Natl. Acad. Sci. 1995 92: 4562-4566.
Teicher B.A. et al. Antiangiogenic Agents Potentiate Cytoxic Cancer Therapies Against Primary and Metastatic Disease.Cancer Research1992 52: 6702-6704.
Watson S. et al. Inhibition of Organ Invasion by the Matrix Metalloproteinase Inhibitor Batimastat (BB-94) in Two Human Colon Carcinoma Metastasis Models.Cancer Research1995 55: 3629-3633.
Weidner N et al. Tumor Angiogenesis and Metastasis—Correlation in Invasive Breast CarcinomaNew. Eng. J. Med. 1991 324: 1-8.
Wolf J. Angiogenesis in Normal and Psoriatic Skin.Laboratory Investigation1989 61: 139-142.
Ceusters Marc André
Luyckx Marcel Gerebernus Maria
Stokbroekx Raymond Antoine
Tuman Robert W.
Van der Aa Marcel Jozef Maria
Janssen Pharmaceutica N.V.
Truong Tamthom N.
Wilson James O.
LandOfFree
Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3739505